Research Article
Th17 Cells and IL-17 As Novel Immune Targets in Ovarian Cancer Therapy
Table 1
The clinical characteristics of ovarian cancer patients.
| | The chosen clinical data | Ovarian cancer (n = 71) |
| | Age (median), years (range) | 57 (22–79) |
| | FIGO stage, n (%) | | Early (I-II) | 25 (35.21%) | | I | 14 (19.72%) | | II | 11 (15.49%) | | Advanced (III-IV) | 46 (64.79%) | | III | 43 (60.56%) | | IV | 3 (4.23%) |
| | Degree of histological differentiation, n (%) | | Intermediate grade (G2) | 35 (49.30%) | | Low grade (G3) | 36 (50.70%) |
| | The OC classification according Kurman and Shih, n (%) | | Type I (serous G2, mucinous, endometrioid) | 42 (59.15%) | | Type II (serous G3) | 26 (40.85%) | | Ca125 range, median (U/ml) | 435.30 (5.71–23935.36) |
|
|
